ADMA Sticks to $530M-$560M 2026 Revenue and a $200M Buyback-Can ASCENIV Growth Silence the Doubters?

ADMA's 2026 revenue target puts trust in the numbers front and center

ADMA Biologics is still defending a $530 million-$560 million 2026 revenue range, but the more important debate is whether investors can trust the base underneath that forecast. The company is also standing by a planned $200 million 2026 total share repurchase initiative, including a $125 million accelerated share repurchase. That does not prove the growth outlook is right, but it does suggest management believes the business has real cash availability now, not just future promise.

The bullish case still hinges on ASCENIV momentum

Bullish investors can support the 2026 plan only if ASCENIV utilization continues to grow and the company's broader forecast remains credible. That is the cleanest path to renewed confidence: sustained ASCENIV demand, stable execution, and numbers that look consistent with underlying business activity.

Culper's allegations keep the credibility debate alive

The bearish case is less about the next quarter and more about the foundation of reported results. Culper Research alleges that real 2025 revenues actually declined 3% year-over-year versus the 20% growth the Company reported. ADMA has publicly rejected those claims, but the allegations still matter because they force investors to scrutinize both growth quality and management's messaging.

That is why recent updates matter so much. Investors are likely to focus on three things:

• whether ASCENIV growth is strong enough to overshadow the dispute
• whether management keeps the 2026 plan intact
• whether the buyback continues to signal financial flexibility